Perseus Proteomics Inc.
4882.T
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.82B
Close$
Share Statistics
| Market cap | $2.82 Billion |
|---|---|
| Enterprise Value | $1.23 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-48.17 |
| Beta | 0.32 |
| Outstanding Shares | 17,098,953 |
Return
| Return on Equity | -60.90% |
|---|---|
| Return on Assets | -44.72% |
| Return on Invested Capital | -46.90% |
Valuation & Multiples
| P/E Ratio | -3.18 |
|---|---|
| PEG | -21.12 |
| Price to Sales | 19.13 |
| Price to Book Ratio | 2.15 |
| Enterprise Value to Revenue | 8.34 |
| Enterprise Value to EBIT | -1.65 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Perseus Proteomics Inc.
35 employees
CEO: Takuya Yokokawa Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody d...